Vnitr Lek 2007, 53(10):1029-1030

Rituximab (antiCD20 monoklonální protilátka) a molekulárně biologická negativita po léčbě nemocných s folikulárním lymfomem - cesta k vyléčení? - editorial

M. Trněný
I. interní klinika 1. lékařské fakulty UK a VFN Praha, přednosta prof. MUDr. Pavel Klener, DrSc.

Received: July 20, 2007; Published: October 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Trněný M. Rituximab (antiCD20 monoklonální protilátka) a molekulárně biologická negativita po léčbě nemocných s folikulárním lymfomem - cesta k vyléčení? - editorial. Vnitr Lek. 2007;53(10):1029-1030.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Belada D et al. Dosažení Bcl-2/IgH negativity v periferní krvi/kostní dřeni po léčbě je u nemocných s folikulárním lymfomem spojeno s lepší prognózou onemocnění. Vnitř Lék 2007; 53: 1057-1063. Go to PubMed...
    2. Besa PC, McLaughlin PW, Cox JD et al. Long term assessment of patterns of treatment failure and survival in patients with stage I or II follicular lymphoma. Cancer 1995; 75: 2361-2367. Go to original source...
    3. Colombat P, Salles G, Brousse N et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001; 97:101-106. Go to original source... Go to PubMed...
    4. Czuczman MS, Grillo-Lopez AJ, Mclaughlin P et al. Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy. Ann Oncol 2001; 12: 109-114. Go to original source... Go to PubMed...
    5. Finke J, Slanina J, Lange W et al. Persistence of circulating t(14;18)-positive cells in long-term remission after radiation therapy for localized-stage follicular lymphoma. J Clin Oncol 1993; 11: 1668-1673. Go to original source... Go to PubMed...
    6. Foran JM, Gupta RK, Cunningham D et al. A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response. Br J Haematol 2000; 109: 81-88. Go to original source... Go to PubMed...
    7. Foussard C, Mounier N, Van Hoof A et al. Update of the FL2000 randomized trial combining rituximab to CHVP-Interferon in follicular lymphoma (FL) patients (pts). J Clin Oncol (Meeting Abstracts) 2006; 24: 7508. Go to original source...
    8. Gribben JG, Neuberg D, Freedman AS et al. Detection by Polymerase Chain Reaction of Residual Cells with the bcl-2 Translocation Is Associated with Increased Risk of Relapse After Autologous Bone Marrow Transplantation for B-Cell Lymphoma. Blood 1993; 81: 3449-3457. Go to original source...
    9. Herold M, Pasold R, Srock S et al. Results of a Prospective Randomised Open Label Phase III Study Comparing Rituximab Plus Mitoxantrone, Chlorambucile, Prednisolone Chemotherapy (R-MCP) Versus MCP Alone in Untreated Advanced Indolent Non-Hodgkin's Lymphoma (NHL) and Mantle-Cell-Lymphoma (MCL). ASH Annual Meeting Abstracts 2004; 104: 584. Go to original source...
    10. Hiddemann W, Kneba M, Dreyling M et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005; 106: 3725-3732. Go to original source... Go to PubMed...
    11. Horning SJ. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 1993; 20: 75-88.
    12. Janikova-Oborilova A, Mayer J, Dvorakova D et al. Praktické aspekty a reálný klinický význam sledování t(14,18) vperiferní krvi pacientů s folikulárním lymfomem. Čas Lék Česk 2007; 146: 374-381. Go to PubMed...
    13. Juweid ME, Stroobants S, Hoekstra OS et al. Use of Positron Emission Tomography for Response Assessment of Lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007; 25: 571-578. Go to original source... Go to PubMed...
    14. Mac Manus MP, Hoppe RT. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol 1996; 14: 1282-1290. Go to original source... Go to PubMed...
    15. Marcus R, Imrie K, Belch A et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005; 105: 1417-1423. Go to original source... Go to PubMed...
    16. Mclaughlin P, Grillo L, Link BK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825-2833. Go to original source... Go to PubMed...
    17. Van Oers MHJ, Klasa R, Marcus RE et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006; 108: 3295-3301. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.